18. Dezember 2025

The current shareholders have signed an agreement with SK Capital Partners that becomes lead investor in Swixx Biopharma. The key founders and both current private equity investors – HBM and Mérieux – will reinvest alongside SK Capital Partners. The closing of the transaction is subject to customary regulatory approvals.

Swixx Biopharma Group operates as trusted multi-regional commercialization partner for innovative biotech and pharma companies with a focus on the activities in Central and Eastern Europa and Latin America.

Walder Wyss acted as the legal advisor to Swixx Biopharma and its shareholders on all aspects of the transaction.

The Walder Wyss team was led by Markus Vischer and Samuel Lieberherr (both Corporate/M&A) and included Stefan Knobloch, Hans-Jakob Diem, Dominik Aerni, Nico Bernhard, Angela Diener, Dominik Lusti, Ramona Hutter (all Corporate/M&A), Thomas Meister (Tax), Gion Giger (Antitrust/Competition) and Valentin Wiesner (Banking & Finance).